These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14501797)

  • 21. Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation.
    Roberts L; Liebenberg L; Barnabas S; Passmore JA
    Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):441-9. PubMed ID: 22429786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update.
    Lard-Whiteford SL; Matecka D; O'Rear JJ; Yuen IS; Litterst C; Reichelderfer P;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):541-52. PubMed ID: 15097296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microbicides: a new hope for HIV prevention.
    ; Gupta SK
    Indian J Med Res; 2011 Dec; 134(6):939-49. PubMed ID: 22310826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The design of prophylactic trials for HIV: the case of microbicides.
    Stein ZA; Myer L; Susser M
    Epidemiology; 2003 Jan; 14(1):80-3; discussion 83-4. PubMed ID: 12500050
    [No Abstract]   [Full Text] [Related]  

  • 25. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies.
    McGowan I; Taylor DJ
    Sex Transm Dis; 2010 Jun; 37(6):361-4. PubMed ID: 20514687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection.
    Dhawan D; Mayer KH
    J Infect Dis; 2006 Jan; 193(1):36-44. PubMed ID: 16323129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential use of protease inhibitors as vaginal and colorectal microbicides.
    Herrera C; Shattock RJ
    Curr HIV Res; 2012 Jan; 10(1):42-52. PubMed ID: 22264045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbicides: a new frontier in HIV prevention.
    McGowan I
    Biologicals; 2006 Dec; 34(4):241-55. PubMed ID: 17097303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting product adherence in a topical microbicide safety trial in Pune, India.
    Tolley EE; Tsui S; Mehendale S; Weaver MA; Kohli R
    AIDS Behav; 2012 Oct; 16(7):1808-15. PubMed ID: 21877203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should microbicides be controlled by women or by physicians?
    Piret J; Bergeron MG
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e14-7. PubMed ID: 20932483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The slow evolution of microbicides for STD/HIV prevention.
    Howes J; Bass M
    J Gend Specif Med; 1999; 2(3):22-3. PubMed ID: 11252848
    [No Abstract]   [Full Text] [Related]  

  • 32. Will microbicide trials yield unbiased estimates of microbicide efficacy?
    Trussell J; Dominik R
    Contraception; 2005 Dec; 72(6):408-13. PubMed ID: 16307961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microbicides: an emerging science of HIV-1 prevention in women-15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 3-6 February 2008.
    Saïdi H
    Rev Med Virol; 2009 Mar; 19(2):69-76. PubMed ID: 19086006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda.
    Cox AP; Foss AM; Shafer LA; Nsubuga RN; Vickerman P; Hayes RJ; Watts C; White RG
    Sex Transm Infect; 2011 Dec; 87(7):635-9. PubMed ID: 21768615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Barrier methods for human immunodeficiency virus prevention.
    Eaton EF; Hoesley CJ
    Infect Dis Clin North Am; 2014 Dec; 28(4):585-99. PubMed ID: 25455315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
    Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Condom effectiveness in reducing heterosexual HIV transmission.
    Weller S; Davis K
    Cochrane Database Syst Rev; 2001; 2002(3):CD003255. PubMed ID: 11687062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide.
    Bélec L; Jenabian MA; Charpentier C; Saïdi H
    Future Microbiol; 2011 Jul; 6(7):731-7. PubMed ID: 21797688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA.
    Verguet S; Walsh JA
    Sex Transm Infect; 2010 Jun; 86(3):212-6. PubMed ID: 20522634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravaginal and intrarectal microbicides to prevent HIV infection.
    Balzarini J; Van Damme L
    CMAJ; 2005 Feb; 172(4):461-4. PubMed ID: 15710933
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.